502 related articles for article (PubMed ID: 34626838)
21. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Nishio M; Barlesi F; West H; Ball S; Bordoni R; Cobo M; Longeras PD; Goldschmidt J; Novello S; Orlandi F; Sanborn RE; Szalai Z; Ursol G; Mendus D; Wang L; Wen X; McCleland M; Hoang T; Phan S; Socinski MA
J Thorac Oncol; 2021 Apr; 16(4):653-664. PubMed ID: 33333328
[TBL] [Abstract][Full Text] [Related]
22. Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T; Sakaguchi C; Hirano K; Kobe H; Ishida M; Nakano T; Tachibana Y; Tamiya N; Shiotsu S; Takeda T; Yamada T; Yokoyama T; Tsuchiya M; Nagasaka Y
Thorac Cancer; 2023 Apr; 14(11):1004-1011. PubMed ID: 36866788
[TBL] [Abstract][Full Text] [Related]
23. First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study.
Wu Y; Du B; Lv C; Ji X; Lan Y; Yao N; Zhu Y; Lai J
Ann Med; 2023; 55(2):2243967. PubMed ID: 37557185
[TBL] [Abstract][Full Text] [Related]
24. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
Ikeuchi N; Igata F; Kinoshita E; Kawabata T; Tan I; Osaki Y; Otsuka R; On R; Ikeda T; Nakao A; Sasaki T; Aoyama T; Hirano R; Harada T; Ebi N; Fujita M; Inoue H
Anticancer Res; 2023 Feb; 43(2):713-724. PubMed ID: 36697078
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari KS; Colombo N; Monk BJ; Dubot C; Cáceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüs M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Toker S; Keefe SM; Lorusso D
JAMA Oncol; 2024 Feb; 10(2):185-192. PubMed ID: 38095881
[TBL] [Abstract][Full Text] [Related]
26. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
Lam TC; Tsang KC; Choi HC; Lee VH; Lam KO; Chiang CL; So TH; Chan WW; Nyaw SF; Lim F; Lau JO; Chik J; Kong FM; Lee AW
Lung Cancer; 2021 Sep; 159():18-26. PubMed ID: 34303276
[TBL] [Abstract][Full Text] [Related]
27. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
28. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
29. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
[TBL] [Abstract][Full Text] [Related]
30. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
31. Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer.
Huang YC; Shen SM; Liu CY; Pavlidis S; Wang CL; Ko HW; Chung FT; Lin TY; Feng PH; Lee KY; Guo YK; Yang CT; Kuo CS
Thorac Cancer; 2018 Dec; 9(12):1648-1655. PubMed ID: 30259696
[TBL] [Abstract][Full Text] [Related]
32. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
[TBL] [Abstract][Full Text] [Related]
33. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
34. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Tang N; Guo J; Zhang Q; Wang Y; Wang Z
Oncotarget; 2016 Jan; 7(3):3635-44. PubMed ID: 26498354
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Yamamoto N; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Yamanaka T; Tanaka M; Takahashi K; Fukuoka M
Lung Cancer; 2021 Jan; 151():20-24. PubMed ID: 33279874
[TBL] [Abstract][Full Text] [Related]
36. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Socinski MA; Garon EB; Reynolds CH; Spigel DR; Olsen MR; Hermann RC; Jotte RM; Beck T; Richards DA; Guba SC; Liu J; Frimodt-Moller B; John WJ; Obasaju CK; Pennella EJ; Bonomi P; Govindan R
J Clin Oncol; 2013 Dec; 31(34):4349-57. PubMed ID: 24145346
[TBL] [Abstract][Full Text] [Related]
37. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.
Steendam CMJ; Ernst SM; Badrising SK; Paats MS; Aerts JGJV; de Langen AJ; Dingemans AC
Lung Cancer; 2023 Jul; 181():107248. PubMed ID: 37216839
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
Halmos B; Burke T; Kalyvas C; Vandormael K; Frederickson A; Piperdi B
Lung Cancer; 2021 May; 155():175-182. PubMed ID: 33839603
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
